ARTICLE | Company News
MaxCyte partners with Kite, CRISPR in nonviral gene editing deals
November 16, 2018 5:33 PM UTC
MaxCyte Inc. (LSE:MXCT) partnered with Kite Pharma Inc. and expanded an existing deal with CRISPR Therapeutics AG (NASDAQ:CRSP) to use its Flow Electroporation technology to engineer cells.
Kite gains a non-exclusive license to use MaxCyte's platform for non-viral gene editing. Gilead Sciences Inc. (NASDAQ:GILD) and its Kite unit did not respond to inquiries. ...